ESMO 2024 Press Conference
WEBSep 13, 2024 · The ESMO Congress 2024 will hold a press conference to introduce and discuss the “Eyes to the Future” Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.
From Practice-Changing Data to Future Innovation, Patient Outcome
WEBDate: 13 Sep 2024. Studies presented at the ESMO Congress 2024 bring immunotherapy into new disease areas with high unmet need. Novel agents and technologies show promise in various indications and offer a glimpse into the future of oncology.
Transcenta Updates Encouraging Efficacy Data from First-line
WEB23 hours ago · The updated data has been featured as a poster presentation (Abstract #1419p) on September 16, 2024 at the ESMO Congress 2024 in Barcelona, Spain. “The updated data from the Cohort-G trial of Osemitamab (TST001) in combination with Nivolumab and CAPOX as first-line treatment for advanced G/GEJ cancer are …
Highlights from ESMO 2024: Key Oncology Advances from Major ...
WEB2 days ago · T he 2024 European Society for Medical Oncology (ESMO) Congress illuminated a range of transformative advances that are set to reshape the oncology field.This year’s event underscored the pivotal role of groundbreaking research and innovative treatments in advancing cancer care. Highlights included AbbVie’s updates on novel antibody-drug conjugates targeting ovarian cancer and c-Met ...
ESMO Congress 2024
WEBSep 13, 2024 · The ESMO Congress is a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. ESMO 2024 disseminated the latest cutting-edge data, provided high quality education and excellent networking opportunities for oncologists and other ...
ESMO Congress 2024 - Daily Reporter
WEBAdding durvalumab to neoadjuvant chemotherapy improves survival in muscle-invasive bladder cancer. Practice changing results of event-free survival and overall survival are reported from the NIAGARA study. 15 Sept 2024.
ESMO 2024: Promising results in immunotherapy and antibody …
WEB4 days ago · Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard ...
ESMO Congress 2024 - Daily Reporter
WEBSep 6, 2024 · Taxane- and anthracycline-sparing regimens show promise in high-risk, early-stage breast cancer. 14 Sept 2024. 1. 2. The Daily Reporter is a service from ESMO, Europe’s leading medical oncology society.
Promising antitumour activity for emerging targets - dailyreporter.esmo…
WEB5 days ago · At the ESMO Congress 2024 (Barcelona, 13–17 September), some early-phase trials described promising strategies to target emerging actionable mutations in different solid tumours, such as methylthioadenosine phosphorylase (MTAP) deletion, KRAS G12D mutation, and CDK4 and 2, reporting good tolerability and antitumour activity for novel targeted ...
ESMO 2024: breaking news and abstracts - Oncology Central
WEBWith ESMO 2024 (13–17 September, Barcelona, Spain) underway, we're excited to bring you the latest breaking news, late-breaking abstracts and highlights from this year's congress. From groundbreaking trials to innovative research developments, this collection captures the most impactful moments. Stay tuned as we dive into the stories that ...
- Some results have been removed
Skip to content